Intuitive Surgical, the maker of the da Vinci surgical robot, delivered a solid second quarter that beat analyst expectations on both earnings and revenue. Yet the stock fell more than 9% in after-hours trading, as investors focused on the company's decision to keep its 2026 procedure growth forecast unchanged.
Strong Q2 Results
The company reported adjusted earnings of $2.80 per share, beating the $2.50 expected by analysts polled by LSEG. Revenue came in at $2.89 billion, above the $2.82 billion consensus estimate. The key driver was da Vinci-assisted procedure volumes, which rose 15% year-on-year in the second quarter, as hospitals continue to work through backlogs and expand the use of minimally invasive surgery.
Intuitive Surgical also raised its 2026 adjusted gross margin forecast to 68-69%, up from the previous range of 67.5-68.5%. This suggests the company believes it can protect profitability even if growth moderates.
Why the Stock Fell
Despite the earnings beat, management left its 2026 worldwide procedure growth outlook unchanged at 13.5% to 15.5% and indicated it expects to land near the midpoint of that range. For a company whose stock is priced for years of rapid expansion, maintaining rather than raising long-term guidance can disappoint investors who were hoping for signs of acceleration.
This caution comes against a backdrop of uncertainty in the hospital sector. Some large operators, including HCA Healthcare, have flagged softer patient demand and an increase in uninsured patients after pandemic-era Affordable Care Act subsidies expired. That context may explain why Intuitive chose not to lift its procedure growth forecast, even after a strong quarter.
The market reaction echoes a pattern seen with other growth companies: when expectations don't rise, investors typically pay a lower price for each dollar of future profit, which can show up as a lower valuation multiple. This dynamic is similar to what happened with Elevance Health, which also raised its outlook after a strong quarter but saw its stock fall.
What It Means for Investors
For everyday investors, the key takeaway is that for companies priced for high growth, the market often cares more about the trajectory of future demand than a single quarter's results. Intuitive's unchanged 2026 procedure guidance gave analysts little reason to lift long-term volume and revenue forecasts, even though Q2 procedure volumes grew 15%.
The move also serves as a read-through for other premium-valued medtech names. If their stocks are anchored to procedure-growth assumptions, unchanged guidance can outweigh an earnings beat. This is a reminder that valuation matters: when a stock trades at a high price relative to earnings, any hint that growth might slow can trigger a sharp revaluation.
On the positive side, Intuitive's raised gross margin forecast suggests the company is confident in its ability to manage costs and maintain profitability. This could provide some support for the stock over the longer term, especially if procedure growth remains solid.
Investors will now watch for updates on hospital spending trends and patient volumes, which could influence Intuitive's future guidance. The company's performance also has implications for the broader medtech sector, as it is often seen as a bellwether for surgical robotics and minimally invasive procedures.
For context, other companies have faced similar market reactions recently. GE Aerospace lifted its 2026 profit outlook on strong engine service demand, while Telenor saw its shares plunge 12% after cutting 2026 targets. These examples highlight how forward guidance can move stocks more than past results.
In summary, Intuitive Surgical's Q2 beat was overshadowed by steady long-term guidance, reminding investors that in growth stocks, the future matters most.
